PURPOSE: We have developed a method of quantitation for correcting tissue absorption in in vivo bioluminescence imaging (BLI). PROCEDURES: Variations of luciferin emission spectrum were determined and were related to photon absorption to determine a correction curve. This was validated by combining BLI with tomoscintigraphy and tomodensitometry, which were applied to a lymphoma model. RESULTS: Tissue absorption affects luciferin emission spectrum, mainly for wavelengths less than 620 nm. So, we have selected two filters bordering 620 nm to quantify spectral modifications. A significant correlation was obtained between the spectral analysis and the percentage of transmitted light through tissues (R(2) = 0.97). On a disseminated tumour model, we have shown that such a methodology is of great interest to compare bioluminescent signals and to get more accurate quantitative data about tumour proliferation. CONCLUSIONS: Spectral analysis allows improved quantitation of BLI and could be of value to perform pharmacological studies and to follow tumour progression in models with tumours evolving in different locations.
PURPOSE: We have developed a method of quantitation for correcting tissue absorption in in vivo bioluminescence imaging (BLI). PROCEDURES: Variations of luciferin emission spectrum were determined and were related to photon absorption to determine a correction curve. This was validated by combining BLI with tomoscintigraphy and tomodensitometry, which were applied to a lymphoma model. RESULTS: Tissue absorption affects luciferin emission spectrum, mainly for wavelengths less than 620 nm. So, we have selected two filters bordering 620 nm to quantify spectral modifications. A significant correlation was obtained between the spectral analysis and the percentage of transmitted light through tissues (R(2) = 0.97). On a disseminated tumour model, we have shown that such a methodology is of great interest to compare bioluminescent signals and to get more accurate quantitative data about tumour proliferation. CONCLUSIONS: Spectral analysis allows improved quantitation of BLI and could be of value to perform pharmacological studies and to follow tumour progression in models with tumours evolving in different locations.
Authors: P Workman; A Balmain; J A Hickman; N J McNally; A M Rohas; N A Mitchison; C G Pierrepoint; R Raymond; C Rowlatt; T C Stephens Journal: Lab Anim Date: 1988-07 Impact factor: 2.471
Authors: Nils Ole Schmidt; Mateo Ziu; Giorgio Carrabba; Carlo Giussani; Lorenzo Bello; Yanping Sun; Karl Schmidt; Mitchel Albert; Peter Mcl Black; Rona S Carroll Journal: Clin Cancer Res Date: 2004-02-15 Impact factor: 12.531
Authors: Max Corbett; Willy M Bogers; Jonathan L Heeney; Stefan Gerber; Christian Genin; Arnaud Didierlaurent; Herman Oostermeijer; Rob Dubbes; Gerco Braskamp; Stéphanie Lerondel; Carmen E Gomez; Mariano Esteban; Ralf Wagner; Ivanella Kondova; Petra Mooij; Sunita Balla-Jhagjhoorsingh; Niels Beenhakker; Gerrit Koopman; Sjoerd van der Burg; Jean-Pierre Kraehenbuhl; Alain Le Pape Journal: Proc Natl Acad Sci U S A Date: 2008-02-11 Impact factor: 11.205
Authors: Elizabeth M C Hillman; Cyrus B Amoozegar; Tracy Wang; Addason F H McCaslin; Matthew B Bouchard; James Mansfield; Richard M Levenson Journal: Philos Trans A Math Phys Eng Sci Date: 2011-11-28 Impact factor: 4.226